OCEAN(a) CCTA

A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)”

Stadium
inclusie
Middel
Olpasiran
Populatie
Primaire preventie coronairlijden
Fase
III
First Patient In
1 mei 2026
Last Patient In
12 december 2026
Last Patient Last Visit
19 mei 2028

Inclusieperiode, nog 226 dagen over

Studiedirecteur

drs. J. Plomp

Cardioloog

Contact Kantoor

S. Jansen

Studiemanager

De pagina is verlopen.